Meet our Partnering Advisory Board

With larger partnering discussions in view, we recruited our Partnership Advisory Board, comprised of senior executives with leadership experience in value creation and partnering in the pharmaceutical sector.

Angus served as CEO of Shire plc for five years until his retirement in 2013 and was a member of its board of directors for thirteen years. Earlier in his career, Angus held roles of increasing responsibility at ICI, Zeneca, and AstraZeneca.

He is the Chairman of Mallinckrodt, a UK-based leading global specialty pharmaceutical company, and of Revance Therapeutics, a biotechnology company focused on aesthetic medicine. Angus is also an independent director at TherapeuticsMD, an innovative women’s healthcare company, and Lineage Therapeutics, a leader in pluripotent stem cell treatments.


DBA (Honorary)  Coventry University, UK
Chartered Accountant  Institute of Chartered Accountants in England and Wales

Angus led Shire through nine mergers and acquisitions, evolving the company into a global leader. Shire’s acquisitions during his tenure as CEO had a cumulative value exceeding $4 billion.

“I’m always up for advising a company that has the potential to deliver innovative treatments for patients!”

Dominique has more than 35 years of leadership experience successfully commercializing a broad range of biotech and pharmaceutical products in the U.S. and internationally. He served as Senior Vice President and Chief Marketing Officer of Alexion in 2014-2015.

Most recently, he was President and CEO of PDL BioPharma, a company managing a portfolio of healthcare assets. He is a board member of PDL and of Evofem Biosciences.


Dominique was responsible for relaunching the growth of Amgen’s Inflammation Business Unit in 2011-2013, including Enbrel, a leading treatment for rheumatoid arthritis with US revenues exceeding $4 billion.

“The control of inflammation is key to addressing a wide range of unmet medical needs.”

As a biopharma executive and lawyer, Andrew structures deals to facilitate the development and commercialization of new drugs and therapies. He has negotiated and managed licensing and joint venture relationships for Baxter International and other companies on five continents.

He is a board member of Aclaris Therapeutics, Synthorx and Motif Bio, and chairs the board of Landec Inc, a leading innovator in diversified health and wellness solutions.

JD  Stanford Law School, USA

Andrew played an instrumental role in the sale of Medivation to Pfizer for $14 billion, the sale of InterMune to Roche for more than $8 billion, and the sale of ImClone to Eli Lilly for $6.5 billion.

“This is a company that’s addressing a problem that afflicts every human being.”


Prior to Carmine Therapeutics, Don was Chief Business Officer of AskBio, a leading clinical stage developer of gene therapies and technologies. He led the firm’s business development activities, completing four transactions in 2020 before taking a leading role in AskBio’s $4 billion acquisition by Bayer AG.

Originally trained as a molecular biologist before joining McKinsey, Don has since held senior business roles at 3M Company, Smith & Nephew, and The Medicines Company. More recently, he was Chief Business Officer of Histogenics and Sherlock Biosciences. He has also served on the boards of several healthcare companies, including firms involved in joint replacement and repair.

PhD Molecular Biology  University of Missouri-Columbia, USA
MBA  Washington University, USA

In a career spanning academic science, consulting, sales management, and business development, Don has completed transactions exceeding $8 billion and been instrumental in multiple product launches.

“Antibe’s platform promises a major advance in the treatment of pain and inflammation-based disease. This area is overdue for disruption and represents a massive commercial opportunity.”


This is an external link. Click “OK” to continue.